Ivabradine therapy has been demonstrated to decrease B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP)—cardiac dysfunction biomarkers—in patients with heart failure (Table 8) [20,23,29,34]. The gene discussed is NPPB; the disease is heart failure.